NEW YORK (GenomeWeb News) – Epistem today announced a three-year collaboration with Sanofi-Aventis US directed at the use of biomarkers to support the drug manufacturer's oncology programs.
Under the terms of the deal, Epistem will provide Sanofi-Aventis its GenetRx biomarker gene expression profiling technology and immunohistochemistry technologies. Epistem is eligible to receive up to $4 million in research support payments, including reimbursement for certain costs, the Manchester, UK-based biotech firm said.
GenetRx extracts mRNA from tissue biopsies, blood, and small amounts of surrogate tissue to measure drug-induced gene expression changes.
The deal is expected to provide Sanofi-Aventis with a biomarker strategy to identify biological responses to drugs in relevant tissues. "The translational nature of this relationship means activities will cover preclinical, ex vivo, and clinical support," Epistem said.